尼妥珠单抗联合放疗在食管癌放疗后复发患者中的应用分析

Nimotuzumab combined with radiotherapy in recurrence from esophageal carcinoma after radiotherapy

目的:分析食管癌放疗后复发患者应用尼妥珠单抗联合放疗的价值。方法:2012年1月至2013年12月符合纳入标准的食管癌放疗后复发患者28例,分为治疗组(尼妥珠单抗)13例和对照组(单纯放疗)15例。比较两组患者近期缓解率、前2年生存率和不良反应。结果:实验组与对照组治疗结束后,患者近期缓解率分别为92.3%(12/13)和80%(12/15),有统计学差异(P<0.05)。实验组与对照组1年和2年生存率分别为69.2%、46.7%和38.5%、33.3%,有明显统计学差异(P<0.05);两组的不良反应(试管穿孔、出血、放射性食管炎、放射性肺炎,骨髓抑制)无明显统计学差异(P>0.05)。结论:尼妥珠单抗联合放疗可以提高食管癌放疗后局部复发患者的局控率并延长存活期,同时不会增加不良反应。

Objective： To investigate the value of Nimotuzumab combined with radiotherapy in recurrence from esophageal carcinoma after radiotherapy. Methods： Total 28 ceases of patients with recurrence from esophageal carcinoma after radiotherapy from January 2012 to October 2015 were randomly divided into experimental group（ Nimotuzumab combined with radiotherapy 13 ceases） and control group（ irradiation were 15 ceases）. The response rate,first 2-year survival rate and adverse reaction occurrence rate were compared between those two groups. Results： The response rate was 92. 3%（ 12/13） in eaperimental group and 80%（ 12/15） in control group（ P〈 0. 05）. The 1,2-year survival rate were higher in experimental group than those in control group（ 69. 2% vs 46. 7% and 38. 5%vs 33. 3%）,the diference was significant（ P 〈0. 05）. The adverse reaction were similarity in experimental group than those in control group,the diference was not significant（ P〉 0. 05）. Conclusion： Nimotuzumab combined with radiotherapy was an effective therapy in recurrence from esophageal carcinoma after Radiotherapy.